|
16/02/2023
|
07:00
|
Cancellation - 4d Pharma Plc
|
RNS
|
|
15/02/2023
|
13:16
|
Cancellation of admission to trading on AIM
|
RNS
|
|
02/02/2023
|
15:10
|
Updated Results from Renal Cell Carcinoma Cohort
|
RNS
|
|
16/01/2023
|
10:15
|
Result of Meeting
|
RNS
|
|
30/12/2022
|
12:30
|
Update on Administration and Suspension of Trading
|
RNS
|
|
16/11/2022
|
07:00
|
Blautix Phase II Clinical Trial Results Published
|
RNS
|
|
10/11/2022
|
14:00
|
MRx0518 SITC 2022 poster presentations
|
RNS
|
|
05/10/2022
|
13:00
|
MRx0518 poster presentations at SITC 2022
|
RNS
|
|
29/09/2022
|
10:00
|
Update on Suspension of Trading on AIM
|
RNS
|
|
24/08/2022
|
07:00
|
Publication of preclinical autism research
|
RNS
|
|
04/08/2022
|
15:33
|
Publication of Joint Administrators' Proposals
|
RNS
|
|
01/07/2022
|
17:33
|
Temporary Pause of Recruitment in Clinical Trials
|
RNS
|
|
28/06/2022
|
18:28
|
4D Pharma receives Notice of Delisting from NASDAQ
|
RNS
|
|
28/06/2022
|
15:15
|
Result of AGM
|
RNS
|
|
27/06/2022
|
17:30
|
4D Pharma
|
RNS
|
|
24/06/2022
|
18:22
|
Update on Suspension of Trading
|
RNS
|
|
24/06/2022
|
12:30
|
Temporary Suspension
|
RNS
|
|
24/06/2022
|
12:30
|
Suspension - 4D Pharma PLC
|
RNS
|
|
14/06/2022
|
07:00
|
Pre AGM-Investor Presentation and Q&A
|
RNS
|
|
07/06/2022
|
11:00
|
Exercise of Options and Total Voting Rights
|
RNS
|
|
27/05/2022
|
07:00
|
ASCO 2022 MRx0518 and Bavencio Trial In Progress
|
RNS
|
|
25/05/2022
|
13:51
|
Annual Report and Notice of AGM
|
RNS
|
|
17/05/2022
|
07:00
|
ATS 2022 - MRx-4DP0004 Phase I/II Part A poster
|
RNS
|
|
01/04/2022
|
07:00
|
Final Results
|
RNS
|
|
24/03/2022
|
10:50
|
Holding(s) in Company
|
RNS
|
|
23/03/2022
|
07:00
|
MRx0518 + Keytruda - Primary endpoint met in RCC
|
RNS
|
|
21/03/2022
|
10:46
|
Holding(s) in Company
|
RNS
|
|
09/03/2022
|
07:00
|
Form F3 Registration Statement filed with SEC
|
RNS
|
|
24/02/2022
|
07:21
|
Holding(s) in Company
|
RNS
|
|
23/02/2022
|
07:00
|
Participation in Chardan Microbiome Summit
|
RNS
|
|
22/02/2022
|
07:00
|
Parkinson’s trial receives FDA IND clearance
|
RNS
|
|
18/02/2022
|
07:00
|
Restatement of Interim Results to June 30, 2021
|
RNS
|
|
27/01/2022
|
07:00
|
Additional MRx04 Phase 1/2 asthma data and event
|
RNS
|
|
25/01/2022
|
17:17
|
Holding(s) in Company
|
RNS
|
|
20/01/2022
|
07:00
|
4D pharma to host virtual KOL event
|
RNS
|
|
06/01/2022
|
10:07
|
Holding(s) in Company
|
RNS
|
|
05/01/2022
|
07:00
|
Participation in Upcoming Investor Conference
|
RNS
|
|
04/01/2022
|
07:00
|
4D pharma appoints John Doyle as CFO
|
RNS
|
|
04/01/2022
|
07:00
|
Grant of Options
|
RNS
|
|
13/12/2021
|
07:00
|
4D pharma Phase 1/2 asthma study Part A results
|
RNS
|
|
09/12/2021
|
07:00
|
4D pharma presents IBS Phase 2 microbiome analysis
|
RNS
|
|
07/12/2021
|
14:19
|
Holding(s) in Company
|
RNS
|
|
19/11/2021
|
17:58
|
Holding(s) in Company
|
RNS
|
|
11/11/2021
|
07:00
|
4D pharma Jefferies Healthcare Conference
|
RNS
|
|
12/10/2021
|
07:00
|
Jefferies Next Generation IBD Therapeutics Summit
|
RNS
|
|
30/09/2021
|
07:00
|
Half-year Report
|
RNS
|
|
16/09/2021
|
14:08
|
Holding(s) in Company
|
RNS
|
|
15/09/2021
|
07:00
|
4D pharma presents two posters at ESMO Congress
|
RNS
|
|
09/09/2021
|
07:00
|
Participation in Upcoming Investor Conferences
|
RNS
|
|
19/08/2021
|
09:44
|
Holding(s) in Company
|
RNS
|